Back to Archived News
Lifeline Biotechnologies Files Additional Patents on Its First Warning System
Monday, August 31, 2009
Reno, NV -- Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) today announced that it has filed four additional patents on its First Warning System™ methods and technology.
The First Warning System™ has been designed, developed and tested, a process that assists in identifying abnormalities of the breast.
Jim Holmes, Lifeline’s CEO, said that "We are extending patent protection on our proprietary neural net diagnostic technologies with the filing of three additional patent applications in the United States. These filings relate to four essential elements in its system for analyzing temperature readings of breast tissue to identify cancerous tissue. The patents address the First Warning System’s ™ method for the placement of temperature sensors to obtain reliable temperature readings, its method for analyzing the temperature readings, and its placeholder for assuring proper sensor placement. In addition, a fourth application was filed under the Patent Cooperation Treaty (PCT) to extend Lifeline Biotechnologies’ protection, internationally, on all of the existing patent filings and existing intellectual property including these new filings."
Lifeline Biotechnologies previously received two patents on its First Warning System™ hardware and has in the past year filed for a patent on the technological advancements of the First Warning System ™ software. The software has achieved the robust capability of identifying and classifying tissue abnormalities of the breast with sensitivities (ability to identify) of 95% to 100% and specificities (verify) of 87% to 90%. Currently, it is widely recognized that mammograms miss an estimated 20 to 30% of the breast cancers.
Lifeline competes in the money markets for funds to continue the development of its products as well as supporting operating and administrative expenses. The cost of funds for companies such as Lifeline is expensive and the terms have been, and may continue to be, dilutive. The Company is seeking other means of financing in an effort to reduce the dilutive aspects.
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company’s product and regulatory and shareholder approval for anticipated actions.
Back to Archived News